Patent intelligence · US
US 11234994
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
Patent details — US 11234994
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 1, 2022
- Expiration
- Jan 27, 2042
- Applicant
- Benitec Biopharma Limited
- Claims
- 21
- CPC classes
- A61K, A61K31/7105, A61K31/713, A61K48/005
Quick answer
US 11234994 (Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof) is held by Benitec Biopharma Limited. Status: granted. Granted Feb 1, 2022. Expires Jan 27, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Benitec Biopharma Limited
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/7105, A61K31/713, A61K48/005, A61P, A61P11/04
More from Benitec Biopharma Limited
Related pharmaceutical patents in our USPTO index.
-
US 11932852
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 11535851
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
granted -
US 11142765
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 10898505
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
granted -
US 10000753
Age-related macular degeneration treatment
granted -
US 9518260
Pain treatment
granted -
US 9410154
HBV treatment
granted
Frequently asked questions
What is US patent 11234994?
US 11234994 (Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof) is held by Benitec Biopharma Limited. Status: granted. Granted Feb 1, 2022. Expires Jan 27, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11234994?
Benitec Biopharma Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 11234994 expire?
Our index shows an expiration date of Jan 27, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.